CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
CASI Pharmaceuticals (NASDAQ:CASI) will participate at the Guggenheim Healthcare Innovation Conference 2025. The CASI management team is scheduled for a fireside chat on November 12, 2025 at 9:30 AM ET in Boston, MA.
The company noted its focus on CID-103, an investigational anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases. CASI also said it will hold one-on-one investor meetings during the conference.
CASI Pharmaceuticals (NASDAQ:CASI) parteciperà alla conferenza Guggenheim Healthcare Innovation Conference 2025. Il team dirigenziale di CASI è previsto per un dialogo informale sul palco il 12 novembre 2025 alle 9:30 AM ET a Boston, MA.
L'azienda ha evidenziato il suo focus su CID-103, un anticorpo monoclonale anti-CD38 sperimentale per il rigetto degli organi e per malattie autoimmuni. CASI ha inoltre dichiarato che terrà incontri individuali con gli investitori durante la conferenza.
CASI Pharmaceuticals (NASDAQ:CASI) participará en la Conferencia Guggenheim Healthcare Innovation Conference 2025. El equipo directivo de CASI tiene programada una charla frente a la chimenea el 12 de noviembre de 2025 a las 9:30 a. m. hora del Este en Boston, MA.
La empresa señaló su enfoque en CID-103, un anticuerpo monoclonal anti-CD38 en investigación para el rechazo de trasplante de órganos y enfermedades autoinmunes. CASI también dijo que celebrará reuniones individuales con inversores durante la conferencia.
CASI Pharmaceuticals (NASDAQ:CASI)는 2025년 구겐하임 헬스케어 혁신 컨퍼런스에 참가합니다. CASI 경영진은 보스턴, 매사추세츠에서 2025년 11월 12일 동부 표준시 9:30에 파이어사이드 대담을 예정되어 있습니다.
회사는 CID-103에 주목했고, 이는 이식 거부 및 자가면역 질환을 위한 연구 중인 항-CD38 단일클론 항체입니다. 또한 컨퍼런스 기간 동안 CASI는 투자자 일대일 미팅을 개최할 예정이라고 밝혔습니다.
CASI Pharmaceuticals (NASDAQ:CASI) participera à la conférence Guggenheim Healthcare Innovation Conference 2025. L'équipe dirigeante de CASI est prévue pour une discussion informelle sur scène le 12 novembre 2025 à 9h30, heure de l'Est à Boston, MA.
La société a souligné son attention sur CID-103, un anticorps monoclonal anti-CD38 expérimental pour le rejet d'organes et les maladies auto-immunes. CASI a également déclaré qu'elle organiserait des entretiens individuels avec des investisseurs lors de la conférence.
CASI Pharmaceuticals (NASDAQ:CASI) wird an der Guggenheim Healthcare Innovation Conference 2025 teilnehmen. Das CASI-Management-Team ist für ein Fireside-Chat am 12. November 2025 um 9:30 Uhr Eastern Time in Boston, MA vorgesehen.
Das Unternehmen hob seinen Fokus auf CID-103 hervor, einen experimentellen anti-CD38-Monoklonalen Antikörper gegen Organtransplantatabstoßung und Autoimmunerkrankungen. CASI sagte auch, während der Konferenz One-on-One-Investorengespräche abzuhalten.
CASI Pharmaceuticals (NASDAQ:CASI) ستشارك في مؤتمر Guggenheim للابتكار في الرعاية الصحية 2025. من المقرر أن يجري فريق إدارة CASI محادثة على الموقد في 12 نوفمبر 2025 الساعة 9:30 صباحًا بتوقيت شرق الولايات المتحدة في بوسطن، ماساتشوستس.
وقالت الشركة إنها تركّز على CID-103، وهو جسم مضاد أحادي النسيلة مضاد-CD38 قيد البحث لرفض زراعة الأعضاء والأمراض المناعية الذاتية. كما ذكرت أنهم سيعقدون اجتماعات فردية مع المستثمرين خلال المؤتمر.
- None.
- None.
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced that the CASI management team will participate at the Guggenheim Healthcare Innovation Conference 2025 in a fireside chat at 9:30 AM ET on November 12 in Boston, MA. CASI will also host one-on-one meetings with investors at the conference.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a public biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases.
CID-103 is a fully human IgG1, potentially best-in-class, clinical stage, anti-CD38 monoclonal antibody which targets a unique epitope and has demonstrated an encouraging pre-clinical efficacy and clinical safety profile compared to other anti-CD38 monoclonal antibodies, and for which CASI owns exclusive global rights. CASI received FDA IND clearance to conduct a Phase 1 study in renal allograft antibody-mediated rejection (AMR) in the U.S. and plans for first patient in first quarter of 2026. In parallel, CASI is actively recruiting and dosing patients in an ongoing Phase 1 study in immune thrombocytopenia (ITP). In addition, CASI is assessing multiple technologies for development of a stable, high concentration protein solution for subcutaneous injection.
More information on CASI is available at www.casipharmaceuticals.com.
INVESTOR CONTACT:
Ingrid Choong, PhD
650-619-6115
ingridc@casipharmaceuticals.com
SOURCE: CASI Pharmaceuticals
View the original press release on ACCESS Newswire
FAQ
When will CASI (NASDAQ:CASI) present at the Guggenheim Healthcare Innovation Conference 2025?
What will CASI management discuss at the November 12, 2025 Guggenheim conference?
Will CASI (CASI) meet investors at the Guggenheim Healthcare Innovation Conference 2025?
What is CID-103 that CASI will reference at the Guggenheim conference?
Where is the Guggenheim Healthcare Innovation Conference 2025 session with CASI being held?
How can investors access CASI's presentation at the Guggenheim Healthcare Innovation Conference 2025?
